{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:07:45Z","timestamp":1792033665170,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Adelphi Real World"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40487-024-00303-5","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T11:23:52Z","timestamp":1726745032000},"page":"753-774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Study of the Burden of Myelodysplastic Syndromes in Patients and Their Caregivers in Europe and the United States"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-7587","authenticated-orcid":false,"given":"Katie","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellissa","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Trenholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmina","family":"Hogea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"issue":"19","key":"303_CR1","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.3390\/ijms221910232","volume":"22","author":"P Lee","year":"2021","unstructured":"Lee P, Yim R, Yung Y, et al. Molecular targeted therapy and immunotherapy for myelodysplastic syndrome. Int J Mol Sci. 2021;22(19):10232.","journal-title":"Int J Mol Sci."},{"issue":"6","key":"303_CR2","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/bjh.16206","volume":"189","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2020;189(6):1016\u201327.","journal-title":"Br J Haematol"},{"issue":"3","key":"303_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000695","volume":"6","author":"AA van de Loosdrecht","year":"2022","unstructured":"van de Loosdrecht AA, Mandac SI. EHA endorsement of ESMO clinical practice guidelines for diagnosis, treatment, and follow-up for myelodysplastic syndromes. Hemasphere. 2022;6(3): e695.","journal-title":"Hemasphere"},{"issue":"11","key":"303_CR4","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.3390\/diagnostics11111982","volume":"11","author":"T Comont","year":"2021","unstructured":"Comont T, Treiner E, Vergez F. From immune dysregulations to therapeutic perspectives in myelodysplastic syndromes: a review. Diagnos (Basel). 2021;11(11):1982.","journal-title":"Diagnos (Basel)"},{"issue":"1","key":"303_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.6004\/jnccn.2011.0006","volume":"9","author":"MA Sekeres","year":"2011","unstructured":"Sekeres MA. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J Natl Compr Canc Netw. 2011;9(1):57\u201363.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"303_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.leukres.2007.10.015","volume":"32","author":"DP Steensma","year":"2008","unstructured":"Steensma DP, Heptinstall KV, Johnson VM, et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008;32(5):691\u20138.","journal-title":"Leuk Res"},{"issue":"7","key":"303_CR7","first-page":"1629","volume":"12","author":"Y Simoni","year":"2022","unstructured":"Simoni Y, Chapuis N. Diagnosis of myelodysplastic syndromes: from immunological observations to clinical applications. Diagnos (Basel). 2022;12(7):1629.","journal-title":"Diagnos (Basel)."},{"issue":"2","key":"303_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.annonc.2020.11.002","volume":"32","author":"P Fenaux","year":"2021","unstructured":"Fenaux P, Haase D, Santini V, et al. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2020\u2606). Ann Oncol. 2021;32(2):142\u201356.","journal-title":"Ann Oncol"},{"issue":"2","key":"303_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/bjh.17612","volume":"194","author":"SB Killick","year":"2021","unstructured":"Killick SB, Ingram W, Culligan D, et al. British Society for Haematology guidelines for the management of adult myelodysplastic syndromes. Br J Haematol. 2021;194(2):267\u201381.","journal-title":"Br J Haematol"},{"issue":"7","key":"303_CR10","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.3390\/curroncol30070459","volume":"30","author":"J Lucero","year":"2023","unstructured":"Lucero J, Al-Harbi S, Yee KWL. Management of patients with lower-risk myelodysplastic neoplasms (MDS). Curr Oncol. 2023;30(7):6177\u201396.","journal-title":"Curr Oncol"},{"key":"303_CR11","doi-asserted-by":"publisher","first-page":"204062072311833","DOI":"10.1177\/20406207231183330","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yang X, Ma L, Zhang Y, Wei J. Immune dysregulation and potential targeted therapy in myelodysplastic syndrome. Ther Adv Hematol. 2023;14:20406207231183330.","journal-title":"Ther Adv Hematol"},{"issue":"9","key":"303_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e19222","volume":"9","author":"X Guo","year":"2023","unstructured":"Guo X, Yu S, Ren X, Li L. Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome. Heliyon. 2023;9(9): e19222.","journal-title":"Heliyon"},{"issue":"1","key":"303_CR13","doi-asserted-by":"publisher","first-page":"2198098","DOI":"10.1080\/16078454.2023.2198098","volume":"28","author":"Y Du","year":"2023","unstructured":"Du Y, Li C, Yan J. The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis. Hematology. 2023;28(1):2198098.","journal-title":"Hematology"},{"issue":"8","key":"303_CR14","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/bmt.2016.40","volume":"51","author":"A El-Jawahri","year":"2016","unstructured":"El-Jawahri A, Kim HT, Steensma DP, et al. Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transplant. 2016;51(8):1121\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"303_CR15","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.3390\/cancers15153815","volume":"15","author":"MB Gerke","year":"2023","unstructured":"Gerke MB, Christodoulou I, Karantanos T. Definitions, biology, and current therapeutic landscape of myelodysplastic\/myeloproliferative neoplasms. Cancers (Basel). 2023;15(15):3815.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"303_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100940","volume":"4","author":"JJ Rodriguez-Sevilla","year":"2023","unstructured":"Rodriguez-Sevilla JJ, Adema V, Garcia-Manero G, Colla S. Emerging treatments for myelodysplastic syndromes: biological rationales and clinical translation. Cell Rep Med. 2023;4(2): 100940.","journal-title":"Cell Rep Med"},{"issue":"5","key":"303_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11864-023-01084-1","volume":"24","author":"GA Robbins-Welty","year":"2023","unstructured":"Robbins-Welty GA, Webb JA, Shalev D, et al. Advancing palliative care integration in hematology: building upon existing evidence. Curr Treat Opt Oncol. 2023;24(5):542\u201364.","journal-title":"Curr Treat Opt Oncol"},{"issue":"Supplement 1","key":"303_CR18","doi-asserted-by":"publisher","first-page":"8122","DOI":"10.1182\/blood-2022-155893","volume":"140","author":"KW DiNardo","year":"2022","unstructured":"DiNardo KW, Houk A, Shim C, et al. The mental health burden and quality of life impact of myelodysplastic syndromes in patients and their caregivers. Blood. 2022;140(Supplement 1):8122\u20133.","journal-title":"Blood"},{"issue":"11","key":"303_CR19","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-Specific Programmes\u2014a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"303_CR20","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes. Curr Med Res Opin. 2023;39(12):1707\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"303_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8): e010352.","journal-title":"BMJ Open"},{"key":"303_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabet Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabet Metab Syndr Obes"},{"key":"303_CR23","doi-asserted-by":"publisher","first-page":"204062072096612","DOI":"10.1177\/2040620720966121","volume":"11","author":"SG Papageorgiou","year":"2020","unstructured":"Papageorgiou SG, Kotsianidis I, Bouchla A, et al. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. Ther Adv Hematol. 2020;11:2040620720966121.","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"303_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","volume":"15","author":"NJ Devlin","year":"2017","unstructured":"Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. Appl Health Econ Health Policy. 2017;15(2):127\u201337.","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"303_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"303_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"303_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"303_CR28","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1017\/S0714980800012484","volume":"19","author":"R H\u00e9bert","year":"2000","unstructured":"H\u00e9bert R, Bravo G, Pr\u00e9ville M. Reliability, validity and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Can J Aging. 2000;19(4):494\u2013507.","journal-title":"Can J Aging"},{"key":"303_CR29","doi-asserted-by":"crossref","unstructured":"Szende A, Janssen B, Cabases J, (eds). Self-reported population health: an international perspective based on EQ-5D. In: Self-Reported Population Health: An International Perspective based on EQ-5D. Dordrecht (NL): Springer; Copyright 2014, The Editor(s) (if applicable) and the Author(s). 2014.","DOI":"10.1007\/978-94-007-7596-1"},{"issue":"5","key":"303_CR30","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng Y-S, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health"},{"key":"303_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100851","volume":"50","author":"EN Oliva","year":"2021","unstructured":"Oliva EN, Platzbecker U, Fenaux P, et al. Targeting health-related quality of life in patients with myelodysplastic syndromes\u2014current knowledge and lessons to be learned. Blood Rev. 2021;50: 100851.","journal-title":"Blood Rev"},{"key":"303_CR32","unstructured":"Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual (3rd Edition). European Organisation for Research and Treatment of Cancer, Brussels. 2001."},{"key":"303_CR33","unstructured":"Reilly MC. Work productivity and activity impairment questionnaire; Specific health problem, V2.0: Reilly associates. 2010. [Available from: http:\/\/www.reillyassociates.net\/WPAI_SHP.html."},{"key":"303_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12955-015-0222-8","volume":"13","author":"S Amler","year":"2015","unstructured":"Amler S, Sauerland MC, Deiters C, B\u00fcchner T, Schumacher A. Factors influencing life satisfaction in acute myeloid leukemia survivors following allogeneic stem cell transplantation: a cross-sectional study. Health Qual Life Outcomes. 2015;13:28.","journal-title":"Health Qual Life Outcomes"},{"key":"303_CR35","unstructured":"EphRMA. European Pharmaceutical Market Research Association (EphMRA) code of conduct 2019. Association EPMR. 2019."},{"key":"303_CR36","unstructured":"HIPPA. Summary of the HIPAA privacy rule. In: United States Department of Health and Human Services (US HHS). 2003."},{"key":"303_CR37","unstructured":"HIT. Health Information Technology Act. In: (ARRA) ARaRAo, editor. 2009."},{"issue":"7 Suppl","key":"303_CR38","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.amjmed.2012.04.020","volume":"125","author":"BD Smith","year":"2012","unstructured":"Smith BD. Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction. Am J Med. 2012;125(7 Suppl):S26-30.","journal-title":"Am J Med"},{"issue":"8","key":"303_CR39","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.leukres.2015.05.012","volume":"39","author":"G Caocci","year":"2015","unstructured":"Caocci G, Voso MT, Angelucci E, et al. Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. Leuk Res. 2015;39(8):859\u201365.","journal-title":"Leuk Res"},{"issue":"1","key":"303_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/1745017902117010307","volume":"17","author":"JM Giesinger","year":"2021","unstructured":"Giesinger JM, La Nasa G, Sparano F, et al. Health-related quality of life assessment in patients with myelodysplastic syndromes: evidence from randomized clinical trials. Clin Pract Epidemiol Ment Health. 2021;17(1):307\u201314.","journal-title":"Clin Pract Epidemiol Ment Health"},{"issue":"7","key":"303_CR41","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1182\/blood-2003-07-2430","volume":"104","author":"SJ Lee","year":"2004","unstructured":"Lee SJ, Joffe S, Kim HT, et al. Physicians\u2019 attitudes about quality-of-life issues in hematopoietic stem cell transplantation. Blood. 2004;104(7):2194\u2013200.","journal-title":"Blood"},{"key":"303_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/PROM.S346434","volume":"13","author":"J Soper","year":"2022","unstructured":"Soper J, Sadek I, Urniasz-Lippel A, et al. Patient and caregiver insights into the disease burden of myelodysplastic syndrome. Patient Relat Outcome Meas. 2022;13:31\u20138.","journal-title":"Patient Relat Outcome Meas"},{"issue":"6","key":"303_CR43","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/cncr.31193","volume":"124","author":"F Efficace","year":"2018","unstructured":"Efficace F, Cottone F, Abel G, et al. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: an international study in patients with myelodysplastic syndromes. Cancer. 2018;124(6):1251\u20139.","journal-title":"Cancer"},{"issue":"4","key":"303_CR44","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1634\/theoncologist.2019-0348","volume":"25","author":"O Husson","year":"2020","unstructured":"Husson O, de Rooij BH, Kieffer J, et al. The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the \u201creal-world\u201d: results from the population-based PROFILES registry. Oncologist. 2020;25(4):e722\u201332.","journal-title":"Oncologist"},{"key":"303_CR45","doi-asserted-by":"crossref","unstructured":"Frank P, Olshan A, Iraca T, et al. Experiences and support needs of caregivers of patients with higher-risk myelodysplastic syndrome via online bulletin board in the USA, Canada and UK. Oncol Ther. 2023.","DOI":"10.1007\/s40487-023-00253-4"},{"issue":"8","key":"303_CR46","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1038\/s41375-021-01265-7","volume":"35","author":"U Platzbecker","year":"2021","unstructured":"Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021;35(8):2182\u201398.","journal-title":"Leukemia"},{"issue":"9","key":"303_CR47","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","volume":"175","author":"LM DeTora","year":"2022","unstructured":"DeTora LM, Toroser D, Sykes A, et al. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298\u2013304.","journal-title":"Ann Intern Med"},{"key":"303_CR48","unstructured":"International Committee of Medical Journal Editors (ICMJE). Defining the role of authors and contributors 2020. [Available from: http:\/\/www.icmje.org\/recommendations\/browse\/roles-and-responsibilities\/defining-the-role-of-authors-and-contributors.html."}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-024-00303-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-024-00303-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-024-00303-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T15:04:11Z","timestamp":1732115051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-024-00303-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1007\/s40487-024-00303-5","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Katie Lewis, Emily Trenholm and Elliott Brown are employees of Adelphi Real World. Cosmina Hogea and Mellissa Williamson are employees of Gilead Sciences, Inc. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Real World MDS DSP.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Using a checkbox, patients provided informed consent to take part in the survey. No identifiable protected health information was extracted during the course of the survey. Data were collected in such a way that patients and physicians could not be identified directly, with data aggregated before being shared with the subscriber and\/or for publication.The DSP complies with all relevant guidelines and legal obligations. Data were collected according to European Pharmaceutical Marketing Research Association guidelines and thus did not require ethics committee approvals []. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [] and Health Information Technology for Economic and Clinical Health Act legislation [].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}